MassBio’s 2025 Snapshot: VC Gravity, Policy & a Competitiveness Playbook

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c5/b1/39/c5b139ed-cd53-57d0-fed7-9d9eccd39600/mza_4610784360549851808.jpg/600x600bb.jpg

Making Medicine

Incubate Coalition

50 episodes

4 days ago

There's a scientific breakthrough in your medicine cabinet. But how did it get there?

At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.

From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.

In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

Health & Fitness

RSS

All content for Making Medicine is the property of Incubate Coalition and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Health & Fitness

https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/63e60dcfcb6a53b07f7b9849742d611e.jpg

MassBio’s 2025 Snapshot: VC Gravity, Policy & a Competitiveness Playbook | Kendalle Burlin O’Connell

Making Medicine

25 minutes

2 months ago

MassBio’s 2025 Snapshot: VC Gravity, Policy & a Competitiveness Playbook | Kendalle Burlin O’Connell

This week, John Stanford sits down with Kendalle Burlin O’Connell (CEO & President, MassBio) to unpack the 2025 Industry Snapshot - why Massachusetts still attracts 22% of U.S. biotech VC and how advanced modalities keep the state at the cutting edge. We dig into the “flywheel” of the bioeconomy, from NIH and SBIR to FDA uncertainty, tariffs, and MFN. Kendalle lays out a unifying policy roadmap - a comprehensive competitiveness package - to keep the U.S. leading in life sciences. We also talk capital concentration, China’s rapid rise, and what it will take to avoid losing our edge in the next 2-5 years. Stick around for a candid, optimistic close on how the ecosystem rebounds.

What stood out to you most from MassBio’s 2025 Snapshot?
Do you agree the U.S. needs a “comprehensive competitiveness package”- and what should be in it?
How are funding cuts or regulatory uncertainty affecting your team right now?If you're new to the

Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps:
0:00 Intro music & welcome
0:15 Guest intro: Kendalle Burlin O’Connell, MassBio CEO
1:24 2025 MassBio Snapshot: why it matters now
2:12 Key stats: 22% of U.S. VC & advanced modalities lead
3:45 “Massachusetts works”: optimism amid a gloomy market
5:03 The biotech flywheel: how uncertainty stalls the ecosystem
6:59 Funding pipeline: NIH cuts, SBIR reauth, FDA/tariffs/MFN
9:58 Why biotechs need big pharma; price controls’ ripple effects
12:45 Capital crunch: venture down & late-stage concentration
14:51 Why NIH & ARPA-H can’t be replaced by private capital
16:56 The fix: a comprehensive competitiveness package
19:09 China’s rise & the 2-5 year warning
22:23 MA bioeconomy impact, optimism, and outro*We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.”*We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.”